Latest Conference Articles

March 10th 2017, 1:42am

PER® Miami Breast Cancer Conference

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neoadjuvant treatment strategies in HER2-positive breast cancer.

February 27th 2017, 5:08am

Transplantation and Cellular Therapy Meetings

Axicabtagene ciloleucel had an objective response rate of 76% and a complete response rate of 47% in patients with aggressive non-Hodgkin lymphoma followed for at least 1 month.

February 27th 2017, 1:36am

Transplantation and Cellular Therapy Meetings

Prophylactic treatment with letermovir lowered the rates of cytomegalovirus infection and all-cause mortality compared with placebo for CMV-seropositive patients following an allogeneic hematopoietic stem cell transplant.

February 26th 2017, 11:32pm

Transplantation and Cellular Therapy Meetings

Vorinostat combined with tacrolimus and methotrexate represents a potentially effective combination to mitigate graft-versus-host disease in the setting of matched unrelated donor myeloablative conditioning hematopoietic stem cell transplant.

February 26th 2017, 11:13pm

Transplantation and Cellular Therapy Meetings

Francisco Marty, MD, Dana-Farber Cancer Institute, discusses the initial results of the Phase III trial evaluating letermovir for CMV after bone marrow transplant.

February 26th 2017, 10:30pm

Transplantation and Cellular Therapy Meetings

Proper care coordination and patient education are essential to the success of delivering chimeric antigen receptor T-cell therapy, particularly in preparing patients for potential adverse events.

February 26th 2017, 5:10am

Transplantation and Cellular Therapy Meetings

A host of new and emerging therapies for acute and chronic graft-versus-host disease are on the horizon and include B-cell depletion, IL-2, inhibitors of JAK1/JAK2, extracorporeal photopheresis, and the BTK inhibitor ibrutinib.

February 26th 2017, 3:53am

Transplantation and Cellular Therapy Meetings

Sergio A. Giralt, MD, reviewed emerging strategies to improve stem cell transplantation outcomes by reducing the risk of relapse using novel drugs and targeted radiotherapy.

February 26th 2017, 3:43am

Transplantation and Cellular Therapy Meetings

Fred Locke, MD, Moffitt Cancer Center discusses the interim results of the ZUMA-I trial of Kte-C19, a CAR T-cell therapy.

February 26th 2017, 12:11am

Transplantation and Cellular Therapy Meetings

Bart Scott, MD, Fred Hutchinson Cancer Research Center, explains the importance of the intensity of conditioning for stem cell transplants.

February 25th 2017, 8:01pm

Transplantation and Cellular Therapy Meetings

Robert Korngold, PhD, John Theurer Cancer Center looks back on the advances we've made so far in bone marrow transplant.

February 25th 2017, 11:34am

Transplantation and Cellular Therapy Meetings

Treatment with an inactivated varicella zoster virus vaccine, known as V212, lowered the cumulative incidence rate of herpes zoster infection and complications for patients undergoing autologous hematopoietic stem cell transplantation.

February 25th 2017, 5:03am

Transplantation and Cellular Therapy Meetings

Rates of early relapse post-autologous stem cell transplant in patients with relapsing multiple myeloma have not changed over time, but post-relapse survival among early relapsers has improved for patients transplanted after 2005 and for those relapsing since 2008.

February 25th 2017, 4:14am

Transplantation and Cellular Therapy Meetings

Dr. Lancet of Moffitt Cancer Center explains the use of CPX-351 treatment compared to induction chemotherapy, for older adult patients with acute myeloid leukemia.

February 25th 2017, 2:37am

Transplantation and Cellular Therapy Meetings

Partow Kebriaei, MD, discusses the Iomab-B clinical trial for older patients with acute myeloid leukemia.

February 25th 2017, 1:17am

Transplantation and Cellular Therapy Meetings

According to data from a phase I/II clinical trial, carfilzomib can be safely combined with melphalan in a conditioning regimen prior to autologous hematopoietic cell transplantation in patients with relapsed multiple myeloma.

February 23rd 2017, 10:48pm

Transplantation and Cellular Therapy Meetings

More patients with acute myeloid leukemia could proceed to transplant following treatment with CPX-351 compared with the traditional 7+3 chemotherapy regimen.

February 21st 2017, 3:02am

Genitourinary Cancers Symposium (ASCO GU)

At the 2017 Genitourinary Cancers Symposium, Nicholas J. Vogelzang, MD, discussed diagnostic practices and emerging therapies in the field of bladder cancer.

February 21st 2017, 1:29am

Genitourinary Cancers Symposium (ASCO GU)

The combination of cabozantinib and nivolumab, with or without ipilimumab, proved safe and active in advanced genitourinary cancers, particularly urothelial cancer.

February 21st 2017, 1:12am

Genitourinary Cancers Symposium (ASCO GU)

Patients with PD-L1-positive metastatic renal cell carcinoma had a reduction in the risk of progression or death when treated in frontline with the combination of atezolizumab and bevacizumab instead of sunitinib, according to results of a randomized trial.